| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 167 | 2025 | 2066 | 10.130 |
Why?
|
| Veterans | 90 | 2025 | 1766 | 3.740 |
Why?
|
| Pneumococcal Vaccines | 15 | 2016 | 172 | 2.610 |
Why?
|
| Anti-HIV Agents | 28 | 2020 | 344 | 1.740 |
Why?
|
| Antiretroviral Therapy, Highly Active | 27 | 2021 | 269 | 1.600 |
Why?
|
| Middle Aged | 165 | 2025 | 29371 | 1.360 |
Why?
|
| Antibodies, Bacterial | 12 | 2016 | 404 | 1.300 |
Why?
|
| CD4 Lymphocyte Count | 28 | 2022 | 239 | 1.260 |
Why?
|
| Pneumonia, Pneumococcal | 4 | 2014 | 87 | 1.220 |
Why?
|
| Anti-Retroviral Agents | 9 | 2017 | 150 | 1.090 |
Why?
|
| Adult | 131 | 2025 | 31925 | 1.020 |
Why?
|
| Cohort Studies | 62 | 2024 | 5173 | 0.990 |
Why?
|
| Delivery of Health Care | 10 | 2022 | 679 | 0.980 |
Why?
|
| Male | 181 | 2025 | 65815 | 0.980 |
Why?
|
| Humans | 230 | 2025 | 133849 | 0.950 |
Why?
|
| Respiratory Tract Infections | 5 | 2022 | 293 | 0.940 |
Why?
|
| Hepatitis C | 12 | 2020 | 388 | 0.930 |
Why?
|
| Respiratory Protective Devices | 2 | 2021 | 8 | 0.900 |
Why?
|
| Aging | 15 | 2022 | 1304 | 0.840 |
Why?
|
| Alcoholism | 6 | 2025 | 249 | 0.830 |
Why?
|
| Acquired Immunodeficiency Syndrome | 4 | 2021 | 244 | 0.830 |
Why?
|
| Female | 145 | 2025 | 71584 | 0.770 |
Why?
|
| RNA, Viral | 14 | 2025 | 562 | 0.770 |
Why?
|
| Fractures, Bone | 6 | 2023 | 212 | 0.760 |
Why?
|
| HIV-1 | 21 | 2018 | 488 | 0.760 |
Why?
|
| Viral Load | 21 | 2020 | 412 | 0.760 |
Why?
|
| Lymphadenopathy | 1 | 2021 | 31 | 0.740 |
Why?
|
| Osteomyelitis | 3 | 2019 | 211 | 0.740 |
Why?
|
| Myocardial Infarction | 6 | 2020 | 1097 | 0.730 |
Why?
|
| Acute Coronary Syndrome | 2 | 2024 | 234 | 0.720 |
Why?
|
| Health Personnel | 10 | 2021 | 538 | 0.690 |
Why?
|
| Veterans Health | 8 | 2020 | 179 | 0.670 |
Why?
|
| Risk Factors | 45 | 2024 | 11077 | 0.650 |
Why?
|
| United States | 64 | 2024 | 11682 | 0.650 |
Why?
|
| Streptococcus pneumoniae | 11 | 2016 | 383 | 0.630 |
Why?
|
| Bone Diseases | 1 | 2019 | 44 | 0.630 |
Why?
|
| Aged | 64 | 2025 | 21717 | 0.630 |
Why?
|
| Influenza, Human | 6 | 2022 | 691 | 0.630 |
Why?
|
| Liver Cirrhosis | 8 | 2020 | 931 | 0.620 |
Why?
|
| AIDS-Related Opportunistic Infections | 12 | 2015 | 138 | 0.590 |
Why?
|
| Daptomycin | 1 | 2018 | 15 | 0.580 |
Why?
|
| Medication Adherence | 8 | 2018 | 338 | 0.580 |
Why?
|
| Alcohol Drinking | 11 | 2025 | 387 | 0.580 |
Why?
|
| Bacteria | 3 | 2023 | 534 | 0.580 |
Why?
|
| Bacterial Translocation | 1 | 2017 | 23 | 0.570 |
Why?
|
| Cardiovascular Diseases | 6 | 2025 | 2082 | 0.560 |
Why?
|
| Diabetic Foot | 3 | 2019 | 164 | 0.560 |
Why?
|
| Lipopolysaccharide Receptors | 6 | 2017 | 53 | 0.550 |
Why?
|
| Patient Compliance | 5 | 2013 | 479 | 0.540 |
Why?
|
| Vaccines, Conjugate | 4 | 2014 | 82 | 0.540 |
Why?
|
| Incidence | 21 | 2022 | 3393 | 0.520 |
Why?
|
| HIV Seropositivity | 9 | 2013 | 131 | 0.520 |
Why?
|
| Bone and Bones | 1 | 2019 | 310 | 0.520 |
Why?
|
| Gastroenteritis | 4 | 2021 | 365 | 0.510 |
Why?
|
| Alcohol-Related Disorders | 4 | 2020 | 35 | 0.510 |
Why?
|
| Pneumonia | 4 | 2023 | 342 | 0.500 |
Why?
|
| Vaccination | 10 | 2024 | 1011 | 0.490 |
Why?
|
| Hospitals, Veterans | 8 | 2021 | 357 | 0.490 |
Why?
|
| CD4-Positive T-Lymphocytes | 5 | 2020 | 506 | 0.490 |
Why?
|
| Longitudinal Studies | 22 | 2024 | 1488 | 0.490 |
Why?
|
| Neoplasms | 6 | 2022 | 3025 | 0.480 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2018 | 229 | 0.480 |
Why?
|
| Lymphocyte Activation | 2 | 2017 | 724 | 0.480 |
Why?
|
| Substance-Related Disorders | 6 | 2024 | 490 | 0.480 |
Why?
|
| Pneumonia, Viral | 2 | 2018 | 399 | 0.480 |
Why?
|
| Telemedicine | 2 | 2019 | 496 | 0.470 |
Why?
|
| Prospective Studies | 28 | 2022 | 6655 | 0.470 |
Why?
|
| Algorithms | 8 | 2016 | 1732 | 0.460 |
Why?
|
| Proton Pump Inhibitors | 1 | 2017 | 285 | 0.450 |
Why?
|
| HIV | 8 | 2020 | 195 | 0.450 |
Why?
|
| Pneumococcal Infections | 8 | 2016 | 276 | 0.450 |
Why?
|
| Electronic Health Records | 5 | 2018 | 786 | 0.440 |
Why?
|
| Developed Countries | 1 | 2014 | 45 | 0.440 |
Why?
|
| Immunoglobulin G | 9 | 2016 | 823 | 0.430 |
Why?
|
| Primary Health Care | 8 | 2020 | 795 | 0.430 |
Why?
|
| Hepatitis C, Chronic | 6 | 2018 | 373 | 0.420 |
Why?
|
| United States Department of Veterans Affairs | 16 | 2024 | 705 | 0.420 |
Why?
|
| Osteoporotic Fractures | 4 | 2023 | 30 | 0.420 |
Why?
|
| Smoking | 9 | 2016 | 1139 | 0.410 |
Why?
|
| Community-Acquired Infections | 4 | 2020 | 247 | 0.410 |
Why?
|
| Polypharmacy | 3 | 2022 | 40 | 0.400 |
Why?
|
| Hospitalization | 9 | 2025 | 1884 | 0.400 |
Why?
|
| Bacteremia | 4 | 2018 | 417 | 0.390 |
Why?
|
| Biomarkers | 15 | 2021 | 3422 | 0.390 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2025 | 756 | 0.390 |
Why?
|
| Herpes Zoster | 2 | 2024 | 26 | 0.370 |
Why?
|
| Caliciviridae Infections | 3 | 2021 | 358 | 0.360 |
Why?
|
| Bacterial Vaccines | 6 | 1998 | 102 | 0.350 |
Why?
|
| International Classification of Diseases | 4 | 2020 | 99 | 0.340 |
Why?
|
| Case-Control Studies | 14 | 2022 | 3638 | 0.340 |
Why?
|
| Coinfection | 6 | 2019 | 183 | 0.340 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 6 | 2021 | 633 | 0.340 |
Why?
|
| Proportional Hazards Models | 13 | 2024 | 1482 | 0.340 |
Why?
|
| Depression | 7 | 2016 | 1349 | 0.340 |
Why?
|
| Serum Globulins | 1 | 2010 | 8 | 0.340 |
Why?
|
| Masks | 2 | 2021 | 40 | 0.330 |
Why?
|
| Motivational Interviewing | 3 | 2020 | 52 | 0.320 |
Why?
|
| Aged, 80 and over | 19 | 2023 | 7200 | 0.320 |
Why?
|
| Antibodies, Viral | 4 | 2025 | 1204 | 0.320 |
Why?
|
| Blood Proteins | 1 | 2010 | 135 | 0.320 |
Why?
|
| Comorbidity | 17 | 2019 | 1613 | 0.310 |
Why?
|
| Pneumonia, Bacterial | 5 | 2016 | 81 | 0.310 |
Why?
|
| Bartonella | 4 | 1997 | 11 | 0.310 |
Why?
|
| Frailty | 2 | 2023 | 131 | 0.300 |
Why?
|
| Polysaccharides, Bacterial | 3 | 2006 | 70 | 0.300 |
Why?
|
| Meningococcal Vaccines | 1 | 2008 | 30 | 0.300 |
Why?
|
| Cross-Sectional Studies | 17 | 2022 | 3738 | 0.300 |
Why?
|
| Counseling | 5 | 2019 | 240 | 0.290 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 4 | 2017 | 38 | 0.290 |
Why?
|
| Monocytes | 4 | 2016 | 361 | 0.280 |
Why?
|
| Lung Neoplasms | 6 | 2019 | 1789 | 0.270 |
Why?
|
| Population Surveillance | 3 | 2021 | 418 | 0.270 |
Why?
|
| Intensive Care Units | 4 | 2022 | 539 | 0.270 |
Why?
|
| Influenza Vaccines | 2 | 2022 | 491 | 0.260 |
Why?
|
| Survival Analysis | 10 | 2019 | 1596 | 0.260 |
Why?
|
| Treatment Failure | 2 | 2019 | 363 | 0.260 |
Why?
|
| Syphilis | 2 | 2017 | 98 | 0.260 |
Why?
|
| Bone Density | 5 | 2023 | 371 | 0.260 |
Why?
|
| Carcinoma, Hepatocellular | 5 | 2020 | 999 | 0.250 |
Why?
|
| Heart Failure | 5 | 2020 | 2416 | 0.250 |
Why?
|
| Treatment Outcome | 22 | 2025 | 13011 | 0.250 |
Why?
|
| HIV Long-Term Survivors | 2 | 2020 | 5 | 0.250 |
Why?
|
| Stroke Volume | 2 | 2020 | 530 | 0.250 |
Why?
|
| Interleukin-6 | 4 | 2017 | 453 | 0.250 |
Why?
|
| Chemical and Drug Induced Liver Injury | 2 | 2017 | 117 | 0.250 |
Why?
|
| Lung Diseases | 3 | 2020 | 401 | 0.240 |
Why?
|
| Drug Prescriptions | 3 | 2019 | 237 | 0.240 |
Why?
|
| Depressive Disorder | 3 | 2016 | 484 | 0.230 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2020 | 444 | 0.230 |
Why?
|
| Analgesics, Opioid | 3 | 2019 | 458 | 0.230 |
Why?
|
| Texas | 9 | 2020 | 3684 | 0.230 |
Why?
|
| Sleep Wake Disorders | 2 | 2017 | 187 | 0.230 |
Why?
|
| Inflammation | 4 | 2017 | 1595 | 0.230 |
Why?
|
| Anti-Bacterial Agents | 6 | 2022 | 2515 | 0.220 |
Why?
|
| Glycerophospholipids | 2 | 2021 | 8 | 0.220 |
Why?
|
| Quinolines | 1 | 2025 | 112 | 0.220 |
Why?
|
| Liver Neoplasms | 4 | 2020 | 1410 | 0.220 |
Why?
|
| Data Collection | 5 | 2013 | 397 | 0.220 |
Why?
|
| Age Factors | 13 | 2020 | 2975 | 0.220 |
Why?
|
| Retrospective Studies | 18 | 2022 | 17456 | 0.210 |
Why?
|
| Diabetes Complications | 2 | 2012 | 207 | 0.210 |
Why?
|
| Norovirus | 2 | 2020 | 347 | 0.210 |
Why?
|
| Branched DNA Signal Amplification Assay | 1 | 2003 | 1 | 0.210 |
Why?
|
| Staphylococcal Infections | 2 | 2019 | 573 | 0.210 |
Why?
|
| Accidental Falls | 2 | 2022 | 126 | 0.210 |
Why?
|
| Bacteriology | 1 | 2023 | 4 | 0.210 |
Why?
|
| Blood Coagulation Disorders | 2 | 2016 | 106 | 0.200 |
Why?
|
| Young Adult | 16 | 2022 | 9885 | 0.200 |
Why?
|
| Nucleic Acids | 1 | 2023 | 27 | 0.200 |
Why?
|
| Antidepressive Agents | 4 | 2017 | 324 | 0.200 |
Why?
|
| Weight Gain | 2 | 2016 | 414 | 0.200 |
Why?
|
| Salmonella Infections | 2 | 2013 | 32 | 0.200 |
Why?
|
| Absorptiometry, Photon | 2 | 2022 | 205 | 0.200 |
Why?
|
| HIV Protease Inhibitors | 2 | 2016 | 49 | 0.200 |
Why?
|
| Outpatients | 2 | 2021 | 267 | 0.200 |
Why?
|
| Azithromycin | 1 | 2022 | 47 | 0.200 |
Why?
|
| Risk Assessment | 12 | 2023 | 3691 | 0.200 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2015 | 471 | 0.190 |
Why?
|
| Coronavirus OC43, Human | 1 | 2021 | 4 | 0.190 |
Why?
|
| Hip Fractures | 1 | 2023 | 74 | 0.190 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2020 | 134 | 0.190 |
Why?
|
| Orthomyxoviridae Infections | 1 | 2022 | 63 | 0.180 |
Why?
|
| Depressive Disorder, Major | 2 | 2019 | 468 | 0.180 |
Why?
|
| Antiviral Agents | 4 | 2018 | 822 | 0.180 |
Why?
|
| Patient Satisfaction | 3 | 2016 | 504 | 0.180 |
Why?
|
| Severity of Illness Index | 10 | 2020 | 3063 | 0.180 |
Why?
|
| Physician-Patient Relations | 2 | 2016 | 446 | 0.170 |
Why?
|
| Time Factors | 9 | 2021 | 6584 | 0.170 |
Why?
|
| Attitude | 1 | 2021 | 122 | 0.170 |
Why?
|
| Communicable Diseases | 1 | 2023 | 164 | 0.170 |
Why?
|
| Self Report | 4 | 2021 | 551 | 0.170 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2022 | 184 | 0.170 |
Why?
|
| Infection Control | 2 | 2019 | 151 | 0.170 |
Why?
|
| Surveys and Questionnaires | 12 | 2017 | 3987 | 0.170 |
Why?
|
| Cannabis | 1 | 2020 | 52 | 0.160 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2016 | 764 | 0.160 |
Why?
|
| Prevalence | 10 | 2019 | 2654 | 0.160 |
Why?
|
| Patient Admission | 2 | 2019 | 190 | 0.160 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2024 | 291 | 0.160 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2016 | 1406 | 0.160 |
Why?
|
| Viruses | 1 | 2021 | 125 | 0.160 |
Why?
|
| Lymph Nodes | 1 | 2021 | 397 | 0.160 |
Why?
|
| Patient Care Team | 2 | 2016 | 573 | 0.160 |
Why?
|
| Quality of Health Care | 2 | 2013 | 419 | 0.160 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2019 | 42 | 0.160 |
Why?
|
| Defibrillators, Implantable | 1 | 2022 | 196 | 0.160 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2019 | 59 | 0.160 |
Why?
|
| Confidence Intervals | 4 | 2014 | 300 | 0.160 |
Why?
|
| Anti-Infective Agents | 1 | 2022 | 269 | 0.160 |
Why?
|
| Indinavir | 1 | 1998 | 5 | 0.160 |
Why?
|
| Enterococcus | 1 | 2019 | 28 | 0.150 |
Why?
|
| Gynecomastia | 1 | 1998 | 6 | 0.150 |
Why?
|
| Secondary Prevention | 1 | 2020 | 225 | 0.150 |
Why?
|
| Herpes Zoster Vaccine | 1 | 2018 | 11 | 0.150 |
Why?
|
| Vaccination Coverage | 1 | 2018 | 37 | 0.150 |
Why?
|
| Pre-Exposure Prophylaxis | 1 | 2019 | 51 | 0.150 |
Why?
|
| Polymerase Chain Reaction | 4 | 1997 | 1631 | 0.150 |
Why?
|
| Pharmacy | 1 | 2018 | 18 | 0.150 |
Why?
|
| Mandatory Programs | 1 | 2018 | 5 | 0.150 |
Why?
|
| Protease Inhibitors | 1 | 1998 | 100 | 0.150 |
Why?
|
| Methicillin | 1 | 2018 | 43 | 0.150 |
Why?
|
| Rotavirus | 1 | 2021 | 502 | 0.140 |
Why?
|
| Pharmacoepidemiology | 2 | 2018 | 11 | 0.140 |
Why?
|
| Bacteroides Infections | 1 | 1997 | 2 | 0.140 |
Why?
|
| Bacteroides fragilis | 1 | 1997 | 5 | 0.140 |
Why?
|
| Acute-Phase Proteins | 1 | 2017 | 50 | 0.140 |
Why?
|
| Chondrocalcinosis | 1 | 1997 | 15 | 0.140 |
Why?
|
| Respiratory Function Tests | 2 | 2018 | 210 | 0.140 |
Why?
|
| Immunoglobulin M | 2 | 2016 | 224 | 0.140 |
Why?
|
| Immunoglobulin Allotypes | 2 | 1997 | 6 | 0.140 |
Why?
|
| Early Detection of Cancer | 1 | 2021 | 413 | 0.140 |
Why?
|
| Bilirubin | 1 | 2018 | 131 | 0.140 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2018 | 827 | 0.140 |
Why?
|
| Penicillin G Benzathine | 1 | 2017 | 18 | 0.140 |
Why?
|
| Cephalosporins | 1 | 2018 | 143 | 0.140 |
Why?
|
| Health Status | 3 | 2020 | 412 | 0.140 |
Why?
|
| Crack Cocaine | 1 | 1996 | 5 | 0.140 |
Why?
|
| Pharyngitis | 1 | 1997 | 33 | 0.130 |
Why?
|
| Fibronectins | 2 | 2009 | 112 | 0.130 |
Why?
|
| Fatty Liver | 1 | 2019 | 210 | 0.130 |
Why?
|
| Mass Screening | 2 | 2013 | 832 | 0.130 |
Why?
|
| Interleukin-2 | 2 | 2010 | 250 | 0.130 |
Why?
|
| HIV Seronegativity | 3 | 2009 | 30 | 0.130 |
Why?
|
| Membrane Glycoproteins | 2 | 2017 | 432 | 0.130 |
Why?
|
| Fractures, Spontaneous | 1 | 2016 | 18 | 0.130 |
Why?
|
| Locomotion | 1 | 2017 | 69 | 0.130 |
Why?
|
| Arthritis, Infectious | 1 | 1997 | 67 | 0.130 |
Why?
|
| Cooperative Behavior | 3 | 2015 | 233 | 0.130 |
Why?
|
| Hepatitis B Core Antigens | 1 | 2016 | 14 | 0.130 |
Why?
|
| Aspartate Aminotransferases | 4 | 2020 | 86 | 0.130 |
Why?
|
| Parkinson Disease | 1 | 2024 | 732 | 0.130 |
Why?
|
| Communicable Disease Control | 1 | 2018 | 144 | 0.130 |
Why?
|
| Hepatitis B Antibodies | 1 | 2016 | 24 | 0.130 |
Why?
|
| Immunotherapy | 1 | 2022 | 747 | 0.130 |
Why?
|
| Odds Ratio | 6 | 2019 | 1337 | 0.130 |
Why?
|
| Ventricular Function, Left | 1 | 2020 | 541 | 0.130 |
Why?
|
| Ambulatory Care | 2 | 2019 | 412 | 0.130 |
Why?
|
| Salvage Therapy | 1 | 2018 | 202 | 0.130 |
Why?
|
| Bacterial Capsules | 2 | 1996 | 41 | 0.130 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2016 | 54 | 0.130 |
Why?
|
| Logistic Models | 6 | 2019 | 1909 | 0.130 |
Why?
|
| Cost of Illness | 2 | 2020 | 275 | 0.130 |
Why?
|
| Double-Blind Method | 3 | 2025 | 1667 | 0.130 |
Why?
|
| Emphysema | 1 | 2017 | 68 | 0.120 |
Why?
|
| Time-to-Treatment | 1 | 2018 | 202 | 0.120 |
Why?
|
| Lipopolysaccharides | 1 | 2017 | 320 | 0.120 |
Why?
|
| Follow-Up Studies | 8 | 2021 | 5505 | 0.120 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2015 | 39 | 0.120 |
Why?
|
| Intention | 2 | 2013 | 95 | 0.120 |
Why?
|
| Quality Improvement | 1 | 2021 | 690 | 0.120 |
Why?
|
| Smoking Cessation | 2 | 2015 | 209 | 0.120 |
Why?
|
| Hypolipidemic Agents | 2 | 2009 | 187 | 0.120 |
Why?
|
| Buprenorphine | 1 | 2016 | 100 | 0.120 |
Why?
|
| Staphylococcus aureus | 1 | 2019 | 476 | 0.120 |
Why?
|
| DNA Fingerprinting | 1 | 1995 | 109 | 0.120 |
Why?
|
| Biopsy | 1 | 2019 | 1304 | 0.120 |
Why?
|
| Recurrence | 1 | 2019 | 1467 | 0.120 |
Why?
|
| Phagocytosis | 4 | 2008 | 191 | 0.120 |
Why?
|
| CD4 Antigens | 1 | 2014 | 58 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2023 | 1201 | 0.110 |
Why?
|
| Haemophilus influenzae type b | 1 | 2014 | 5 | 0.110 |
Why?
|
| Haemophilus Vaccines | 1 | 2014 | 30 | 0.110 |
Why?
|
| Streptococcal Infections | 1 | 1997 | 248 | 0.110 |
Why?
|
| Positive-Pressure Respiration | 1 | 2014 | 85 | 0.110 |
Why?
|
| Respiratory Insufficiency | 1 | 2017 | 239 | 0.110 |
Why?
|
| Foot Diseases | 1 | 2014 | 23 | 0.110 |
Why?
|
| Obesity | 2 | 2017 | 2410 | 0.110 |
Why?
|
| Sex Characteristics | 2 | 2013 | 335 | 0.110 |
Why?
|
| Cytomegalovirus Infections | 1 | 1996 | 228 | 0.110 |
Why?
|
| Gene Products, vpr | 1 | 2013 | 20 | 0.110 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2016 | 195 | 0.110 |
Why?
|
| Foot | 1 | 2014 | 65 | 0.110 |
Why?
|
| Prehypertension | 1 | 2013 | 11 | 0.110 |
Why?
|
| Respiratory Tract Diseases | 1 | 2014 | 81 | 0.110 |
Why?
|
| Haemophilus Infections | 1 | 2014 | 95 | 0.110 |
Why?
|
| Pulmonary Emphysema | 1 | 2014 | 95 | 0.110 |
Why?
|
| Polysomnography | 1 | 2014 | 151 | 0.100 |
Why?
|
| Salmonella enteritidis | 1 | 2013 | 5 | 0.100 |
Why?
|
| Cough | 1 | 2014 | 96 | 0.100 |
Why?
|
| Quality of Life | 5 | 2012 | 2132 | 0.100 |
Why?
|
| Surgical Procedures, Operative | 1 | 2015 | 188 | 0.100 |
Why?
|
| Body Mass Index | 6 | 2017 | 1709 | 0.100 |
Why?
|
| Polysaccharides | 1 | 2014 | 150 | 0.100 |
Why?
|
| Aneurysm, Infected | 1 | 2013 | 24 | 0.100 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2013 | 128 | 0.100 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2015 | 227 | 0.100 |
Why?
|
| Ritonavir | 2 | 2016 | 48 | 0.100 |
Why?
|
| Observational Studies as Topic | 1 | 2013 | 103 | 0.100 |
Why?
|
| Liver Failure | 1 | 2013 | 91 | 0.100 |
Why?
|
| Peptide Fragments | 2 | 2009 | 833 | 0.100 |
Why?
|
| Viremia | 3 | 2020 | 136 | 0.100 |
Why?
|
| Kidney Diseases | 3 | 2015 | 504 | 0.100 |
Why?
|
| Opioid-Related Disorders | 1 | 2016 | 282 | 0.100 |
Why?
|
| Body Weight | 2 | 2015 | 1034 | 0.100 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2016 | 894 | 0.100 |
Why?
|
| AIDS Serodiagnosis | 1 | 2013 | 57 | 0.100 |
Why?
|
| Alcohol Abstinence | 2 | 2025 | 17 | 0.100 |
Why?
|
| Medical Records | 1 | 2013 | 194 | 0.100 |
Why?
|
| Cause of Death | 3 | 2009 | 502 | 0.100 |
Why?
|
| Hypoglycemic Agents | 1 | 2016 | 479 | 0.100 |
Why?
|
| Brain Ischemia | 1 | 2015 | 278 | 0.100 |
Why?
|
| Integrin alpha5 | 2 | 2009 | 5 | 0.100 |
Why?
|
| Platelet Count | 3 | 2020 | 143 | 0.100 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 1992 | 48 | 0.100 |
Why?
|
| Immunosuppressive Agents | 1 | 2016 | 692 | 0.100 |
Why?
|
| Predictive Value of Tests | 5 | 2020 | 2292 | 0.100 |
Why?
|
| Vasculitis | 1 | 2012 | 51 | 0.100 |
Why?
|
| Prostatic Neoplasms | 1 | 2021 | 1623 | 0.100 |
Why?
|
| Carrier Proteins | 1 | 2017 | 1064 | 0.100 |
Why?
|
| Alanine Transaminase | 3 | 2020 | 162 | 0.100 |
Why?
|
| Spinal Diseases | 1 | 2012 | 46 | 0.090 |
Why?
|
| Walking | 1 | 2014 | 235 | 0.090 |
Why?
|
| DNA, Bacterial | 4 | 1997 | 497 | 0.090 |
Why?
|
| Cross Infection | 1 | 2015 | 332 | 0.090 |
Why?
|
| Prognosis | 7 | 2020 | 5070 | 0.090 |
Why?
|
| Aneurysm, False | 1 | 2013 | 94 | 0.090 |
Why?
|
| Decision Support Techniques | 2 | 2012 | 317 | 0.090 |
Why?
|
| Decompression, Surgical | 1 | 2012 | 92 | 0.090 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2004 | 358 | 0.090 |
Why?
|
| Hemoglobins | 2 | 2015 | 321 | 0.090 |
Why?
|
| Patient Readmission | 1 | 2015 | 412 | 0.090 |
Why?
|
| Life Expectancy | 2 | 2009 | 59 | 0.090 |
Why?
|
| Weight Loss | 1 | 2015 | 516 | 0.090 |
Why?
|
| Spinal Fusion | 1 | 2012 | 114 | 0.090 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2014 | 227 | 0.090 |
Why?
|
| Liver Diseases | 2 | 2014 | 388 | 0.090 |
Why?
|
| Vaccines, Synthetic | 2 | 2022 | 322 | 0.090 |
Why?
|
| Adolescent | 9 | 2022 | 20517 | 0.090 |
Why?
|
| Pandemics | 3 | 2023 | 1196 | 0.090 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 1 | 2010 | 24 | 0.080 |
Why?
|
| Hypergammaglobulinemia | 1 | 2010 | 11 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 2 | 2018 | 1334 | 0.080 |
Why?
|
| Sensitivity and Specificity | 4 | 2020 | 2157 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2015 | 1139 | 0.080 |
Why?
|
| Unsafe Sex | 1 | 2009 | 24 | 0.080 |
Why?
|
| Sputum | 2 | 2023 | 117 | 0.080 |
Why?
|
| Patient Education as Topic | 1 | 2013 | 462 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2019 | 2196 | 0.080 |
Why?
|
| Lipids | 3 | 2014 | 568 | 0.080 |
Why?
|
| Immunization Schedule | 2 | 2021 | 105 | 0.080 |
Why?
|
| Hyperlipidemias | 2 | 2015 | 200 | 0.080 |
Why?
|
| Heptavalent Pneumococcal Conjugate Vaccine | 1 | 2008 | 25 | 0.080 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2009 | 97 | 0.080 |
Why?
|
| Drug Therapy, Combination | 5 | 2012 | 1197 | 0.080 |
Why?
|
| T-Lymphocytes | 1 | 2017 | 1814 | 0.080 |
Why?
|
| Age Distribution | 3 | 2021 | 444 | 0.080 |
Why?
|
| Chronic Disease | 6 | 2014 | 1253 | 0.070 |
Why?
|
| Telephone | 2 | 2020 | 127 | 0.070 |
Why?
|
| Regression Analysis | 4 | 2013 | 830 | 0.070 |
Why?
|
| Mental Health Services | 1 | 2011 | 280 | 0.070 |
Why?
|
| Benzodiazepines | 2 | 2019 | 110 | 0.070 |
Why?
|
| Hypertension | 2 | 2014 | 1391 | 0.070 |
Why?
|
| Virginia | 2 | 2020 | 20 | 0.070 |
Why?
|
| Oligopeptides | 1 | 2008 | 122 | 0.070 |
Why?
|
| Motor Activity | 1 | 2011 | 537 | 0.070 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2008 | 129 | 0.070 |
Why?
|
| Cats | 3 | 1997 | 126 | 0.070 |
Why?
|
| Angiomatosis, Bacillary | 2 | 1997 | 3 | 0.070 |
Why?
|
| Critical Care | 1 | 2013 | 689 | 0.070 |
Why?
|
| Kidney Failure, Chronic | 1 | 2014 | 911 | 0.070 |
Why?
|
| Feces | 2 | 2021 | 786 | 0.070 |
Why?
|
| B-Lymphocytes | 1 | 2010 | 550 | 0.070 |
Why?
|
| Erectile Dysfunction | 1 | 2009 | 208 | 0.070 |
Why?
|
| Stroke | 1 | 2015 | 1071 | 0.060 |
Why?
|
| Pyridines | 1 | 2008 | 247 | 0.060 |
Why?
|
| Hypercholesterolemia | 1 | 2009 | 234 | 0.060 |
Why?
|
| Socioeconomic Factors | 3 | 2020 | 919 | 0.060 |
Why?
|
| Health Services | 1 | 2006 | 73 | 0.060 |
Why?
|
| North America | 2 | 2016 | 260 | 0.060 |
Why?
|
| Program Development | 1 | 2006 | 190 | 0.060 |
Why?
|
| Statistics, Nonparametric | 4 | 2014 | 454 | 0.060 |
Why?
|
| Seasons | 2 | 2018 | 330 | 0.060 |
Why?
|
| Poisson Distribution | 2 | 2018 | 52 | 0.060 |
Why?
|
| Clofibric Acid | 1 | 2004 | 3 | 0.060 |
Why?
|
| Dyslipidemias | 1 | 2008 | 244 | 0.060 |
Why?
|
| Evidence-Based Practice | 2 | 2019 | 116 | 0.060 |
Why?
|
| Sex Factors | 3 | 2014 | 1384 | 0.060 |
Why?
|
| Immunization, Passive | 1 | 2025 | 128 | 0.060 |
Why?
|
| Specialization | 1 | 2005 | 82 | 0.060 |
Why?
|
| Mortality | 2 | 2019 | 262 | 0.060 |
Why?
|
| Interviews as Topic | 3 | 2016 | 418 | 0.050 |
Why?
|
| Medicine | 1 | 2005 | 108 | 0.050 |
Why?
|
| Actinomyces | 1 | 2003 | 4 | 0.050 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2012 | 776 | 0.050 |
Why?
|
| Myocardial Revascularization | 1 | 2024 | 107 | 0.050 |
Why?
|
| Health Care Surveys | 2 | 2016 | 293 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 2 | 2016 | 567 | 0.050 |
Why?
|
| Lung | 2 | 2018 | 1557 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2013 | 866 | 0.050 |
Why?
|
| Drug Resistance, Viral | 1 | 2003 | 50 | 0.050 |
Why?
|
| Disease Progression | 4 | 2012 | 2239 | 0.050 |
Why?
|
| Immunoglobulin Variable Region | 2 | 2003 | 52 | 0.050 |
Why?
|
| Reproducibility of Results | 3 | 2016 | 3050 | 0.050 |
Why?
|
| Statistics as Topic | 1 | 2003 | 261 | 0.050 |
Why?
|
| Lipodystrophy | 1 | 2002 | 33 | 0.050 |
Why?
|
| Behavior Therapy | 1 | 2025 | 268 | 0.050 |
Why?
|
| Hemagglutination Inhibition Tests | 1 | 2022 | 115 | 0.050 |
Why?
|
| Inappropriate Prescribing | 1 | 2022 | 36 | 0.050 |
Why?
|
| Patient Acuity | 1 | 2021 | 68 | 0.050 |
Why?
|
| Kallikreins | 1 | 2021 | 31 | 0.050 |
Why?
|
| Self-Assessment | 1 | 2001 | 65 | 0.050 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2022 | 119 | 0.050 |
Why?
|
| Liver Function Tests | 2 | 2011 | 107 | 0.050 |
Why?
|
| Genotype | 2 | 2020 | 2807 | 0.050 |
Why?
|
| Antibodies, Neutralizing | 1 | 2025 | 494 | 0.040 |
Why?
|
| Feedback | 1 | 2022 | 166 | 0.040 |
Why?
|
| Minority Groups | 1 | 2023 | 255 | 0.040 |
Why?
|
| Dexamethasone | 1 | 2022 | 284 | 0.040 |
Why?
|
| Blood Glucose | 2 | 2016 | 1193 | 0.040 |
Why?
|
| Vital Capacity | 1 | 2020 | 79 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2021 | 307 | 0.040 |
Why?
|
| Cytokines | 2 | 2025 | 1396 | 0.040 |
Why?
|
| Prostate-Specific Antigen | 1 | 2021 | 272 | 0.040 |
Why?
|
| Epidemiologic Methods | 2 | 2011 | 110 | 0.040 |
Why?
|
| Los Angeles | 1 | 2020 | 16 | 0.040 |
Why?
|
| Benzoxazines | 2 | 2012 | 23 | 0.040 |
Why?
|
| Alkynes | 2 | 2012 | 26 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2021 | 604 | 0.040 |
Why?
|
| Georgia | 1 | 2020 | 38 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2003 | 1326 | 0.040 |
Why?
|
| Cell Movement | 2 | 2002 | 917 | 0.040 |
Why?
|
| New York | 1 | 2020 | 73 | 0.040 |
Why?
|
| Cyclopropanes | 2 | 2012 | 70 | 0.040 |
Why?
|
| Faculty, Medical | 1 | 2023 | 281 | 0.040 |
Why?
|
| Diagnosis, Differential | 2 | 2013 | 1976 | 0.040 |
Why?
|
| Autoimmune Diseases | 1 | 2002 | 279 | 0.040 |
Why?
|
| Bartonella henselae | 2 | 1997 | 19 | 0.040 |
Why?
|
| Survivors | 1 | 2021 | 360 | 0.040 |
Why?
|
| Bacterial Typing Techniques | 2 | 1997 | 104 | 0.040 |
Why?
|
| Endothelium, Vascular | 1 | 2002 | 522 | 0.040 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 1998 | 43 | 0.040 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 1998 | 50 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2016 | 1046 | 0.040 |
Why?
|
| Hospitals | 1 | 2021 | 429 | 0.040 |
Why?
|
| Physicians | 1 | 2005 | 630 | 0.040 |
Why?
|
| Reference Values | 2 | 2014 | 742 | 0.040 |
Why?
|
| Geriatric Assessment | 1 | 2019 | 190 | 0.040 |
Why?
|
| Peliosis Hepatis | 1 | 1997 | 1 | 0.040 |
Why?
|
| Absenteeism | 1 | 2018 | 19 | 0.040 |
Why?
|
| Plasma | 1 | 2018 | 104 | 0.040 |
Why?
|
| Occupational Exposure | 1 | 2019 | 139 | 0.040 |
Why?
|
| Protective Factors | 1 | 2018 | 88 | 0.040 |
Why?
|
| Antibody Formation | 2 | 1997 | 278 | 0.040 |
Why?
|
| Health Status Disparities | 1 | 2021 | 246 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2014 | 1489 | 0.040 |
Why?
|
| Efficiency, Organizational | 1 | 2018 | 59 | 0.040 |
Why?
|
| Conjunctivitis | 1 | 1997 | 22 | 0.040 |
Why?
|
| Animals | 9 | 2016 | 36363 | 0.040 |
Why?
|
| Species Specificity | 2 | 1995 | 571 | 0.030 |
Why?
|
| Immunization Programs | 1 | 2018 | 65 | 0.030 |
Why?
|
| Opportunistic Infections | 2 | 2002 | 79 | 0.030 |
Why?
|
| Diagnostic Errors | 1 | 2021 | 344 | 0.030 |
Why?
|
| Reagins | 1 | 2017 | 3 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2021 | 1386 | 0.030 |
Why?
|
| Polyomavirus Infections | 1 | 1998 | 91 | 0.030 |
Why?
|
| Tumor Virus Infections | 1 | 1998 | 141 | 0.030 |
Why?
|
| Simian virus 40 | 1 | 1998 | 196 | 0.030 |
Why?
|
| Phylogeny | 1 | 2020 | 784 | 0.030 |
Why?
|
| CD4-CD8 Ratio | 1 | 2016 | 13 | 0.030 |
Why?
|
| Pharynx | 1 | 1997 | 69 | 0.030 |
Why?
|
| Disease Outbreaks | 2 | 2015 | 330 | 0.030 |
Why?
|
| Carrier State | 1 | 1997 | 77 | 0.030 |
Why?
|
| Injections, Intramuscular | 1 | 2017 | 197 | 0.030 |
Why?
|
| Drug Resistance, Microbial | 1 | 1997 | 194 | 0.030 |
Why?
|
| Sulfonylurea Compounds | 1 | 2016 | 19 | 0.030 |
Why?
|
| Comparative Effectiveness Research | 1 | 2016 | 75 | 0.030 |
Why?
|
| Infant | 3 | 2021 | 13135 | 0.030 |
Why?
|
| South America | 1 | 2016 | 42 | 0.030 |
Why?
|
| Diabetes Mellitus | 2 | 2015 | 933 | 0.030 |
Why?
|
| Antigens, Viral | 1 | 1998 | 440 | 0.030 |
Why?
|
| Opiate Substitution Treatment | 1 | 2016 | 29 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2017 | 148 | 0.030 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 1996 | 157 | 0.030 |
Why?
|
| Thiazolidinediones | 1 | 2016 | 85 | 0.030 |
Why?
|
| Drug Administration Schedule | 2 | 2008 | 755 | 0.030 |
Why?
|
| Coronary Disease | 2 | 2011 | 721 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2022 | 2902 | 0.030 |
Why?
|
| Immunization, Secondary | 1 | 1996 | 111 | 0.030 |
Why?
|
| Blood Bactericidal Activity | 1 | 1995 | 17 | 0.030 |
Why?
|
| Leg | 1 | 2016 | 156 | 0.030 |
Why?
|
| Respiratory Burst | 1 | 1995 | 10 | 0.030 |
Why?
|
| Health Policy | 1 | 2018 | 232 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 1996 | 484 | 0.030 |
Why?
|
| Bartonella Infections | 1 | 1995 | 7 | 0.030 |
Why?
|
| Consensus Sequence | 1 | 1995 | 57 | 0.030 |
Why?
|
| Immunologic Surveillance | 1 | 1995 | 17 | 0.030 |
Why?
|
| Survival Rate | 1 | 2020 | 2207 | 0.030 |
Why?
|
| Bronchoscopy | 1 | 1996 | 173 | 0.030 |
Why?
|
| Computer Simulation | 2 | 2009 | 702 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2018 | 905 | 0.030 |
Why?
|
| Men's Health | 1 | 2015 | 21 | 0.030 |
Why?
|
| Complement Activation | 1 | 1995 | 53 | 0.030 |
Why?
|
| Hepatitis B virus | 1 | 2016 | 142 | 0.030 |
Why?
|
| Canada | 1 | 2016 | 343 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 1 | 1995 | 261 | 0.030 |
Why?
|
| Causality | 1 | 2015 | 94 | 0.030 |
Why?
|
| Albumins | 1 | 2015 | 98 | 0.030 |
Why?
|
| Cytomegalovirus | 1 | 1996 | 271 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2015 | 125 | 0.030 |
Why?
|
| Metformin | 1 | 2016 | 162 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2019 | 1240 | 0.030 |
Why?
|
| Urban Health | 1 | 2014 | 79 | 0.030 |
Why?
|
| Asymptomatic Infections | 1 | 2014 | 29 | 0.030 |
Why?
|
| Rabbits | 1 | 1995 | 736 | 0.030 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1995 | 372 | 0.030 |
Why?
|
| Air Pollutants | 1 | 1996 | 113 | 0.030 |
Why?
|
| Antigens, Bacterial | 1 | 1996 | 320 | 0.030 |
Why?
|
| DNA Primers | 1 | 1995 | 671 | 0.030 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2014 | 77 | 0.030 |
Why?
|
| Mental Disorders | 1 | 2001 | 878 | 0.030 |
Why?
|
| Chromatography, Thin Layer | 1 | 2013 | 50 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2015 | 279 | 0.030 |
Why?
|
| 3T3-L1 Cells | 1 | 2013 | 55 | 0.030 |
Why?
|
| Fluconazole | 1 | 1994 | 50 | 0.030 |
Why?
|
| Phenytoin | 1 | 1994 | 64 | 0.030 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2017 | 589 | 0.030 |
Why?
|
| Peritonitis | 1 | 2014 | 79 | 0.030 |
Why?
|
| Registries | 1 | 2020 | 1561 | 0.030 |
Why?
|
| Social Stigma | 1 | 2014 | 83 | 0.030 |
Why?
|
| PPAR alpha | 1 | 2013 | 54 | 0.030 |
Why?
|
| Brain Neoplasms | 1 | 2003 | 1409 | 0.030 |
Why?
|
| Ascites | 1 | 2014 | 99 | 0.030 |
Why?
|
| User-Computer Interface | 1 | 2014 | 166 | 0.030 |
Why?
|
| PPAR gamma | 1 | 2013 | 86 | 0.030 |
Why?
|
| Radiography, Thoracic | 1 | 2014 | 152 | 0.030 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2014 | 74 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2013 | 317 | 0.030 |
Why?
|
| Radiography, Abdominal | 1 | 2013 | 49 | 0.030 |
Why?
|
| Urine | 1 | 2013 | 83 | 0.030 |
Why?
|
| Ceftriaxone | 1 | 2013 | 70 | 0.030 |
Why?
|
| Alcohols | 1 | 2012 | 18 | 0.020 |
Why?
|
| HIV Antibodies | 1 | 2013 | 71 | 0.020 |
Why?
|
| Blood | 1 | 2013 | 105 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2013 | 129 | 0.020 |
Why?
|
| Neutrophils | 1 | 1995 | 401 | 0.020 |
Why?
|
| Pelvis | 1 | 2013 | 73 | 0.020 |
Why?
|
| Perception | 1 | 2014 | 234 | 0.020 |
Why?
|
| Emtricitabine | 1 | 2012 | 3 | 0.020 |
Why?
|
| Linear Models | 1 | 2014 | 722 | 0.020 |
Why?
|
| Tenofovir | 1 | 2012 | 23 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 1996 | 1760 | 0.020 |
Why?
|
| Radiography | 1 | 2014 | 825 | 0.020 |
Why?
|
| Organophosphonates | 1 | 2012 | 21 | 0.020 |
Why?
|
| Risk | 1 | 2014 | 831 | 0.020 |
Why?
|
| Rickettsiaceae | 1 | 1992 | 1 | 0.020 |
Why?
|
| Peripheral Arterial Disease | 1 | 2016 | 311 | 0.020 |
Why?
|
| Rickettsiaceae Infections | 1 | 1992 | 2 | 0.020 |
Why?
|
| Patient Care | 1 | 2013 | 104 | 0.020 |
Why?
|
| Patient Participation | 1 | 2014 | 234 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2012 | 84 | 0.020 |
Why?
|
| Overweight | 1 | 2015 | 384 | 0.020 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2014 | 239 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2013 | 240 | 0.020 |
Why?
|
| Acute Disease | 1 | 2015 | 1189 | 0.020 |
Why?
|
| Factor Analysis, Statistical | 1 | 2012 | 230 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 1992 | 259 | 0.020 |
Why?
|
| Child | 3 | 2021 | 25712 | 0.020 |
Why?
|
| Adenine | 1 | 2012 | 122 | 0.020 |
Why?
|
| Mice | 4 | 2016 | 18883 | 0.020 |
Why?
|
| Nurse Administrators | 1 | 2011 | 5 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2013 | 455 | 0.020 |
Why?
|
| Proteins | 1 | 2017 | 1087 | 0.020 |
Why?
|
| Ambulatory Care Facilities | 1 | 2013 | 239 | 0.020 |
Why?
|
| Bacterial Infections | 1 | 2014 | 325 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2016 | 711 | 0.020 |
Why?
|
| Health Surveys | 1 | 2011 | 258 | 0.020 |
Why?
|
| Vancomycin | 1 | 1992 | 236 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2013 | 505 | 0.020 |
Why?
|
| Pharmacists | 1 | 2011 | 99 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2015 | 1083 | 0.020 |
Why?
|
| Osteoporosis | 1 | 2011 | 137 | 0.020 |
Why?
|
| Medicare | 1 | 2013 | 464 | 0.020 |
Why?
|
| Pulmonary Fibrosis | 1 | 2010 | 110 | 0.020 |
Why?
|
| Poverty | 1 | 2013 | 435 | 0.020 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2009 | 45 | 0.020 |
Why?
|
| Syndrome | 2 | 2002 | 1165 | 0.020 |
Why?
|
| Length of Stay | 1 | 2015 | 1380 | 0.020 |
Why?
|
| Pneumonia, Staphylococcal | 1 | 2008 | 18 | 0.020 |
Why?
|
| Adjuvants, Immunologic | 1 | 2010 | 390 | 0.020 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2008 | 38 | 0.020 |
Why?
|
| Antigens, CD | 2 | 2004 | 452 | 0.020 |
Why?
|
| Atazanavir Sulfate | 1 | 2008 | 6 | 0.020 |
Why?
|
| Gene Expression Regulation | 2 | 2009 | 2656 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2014 | 1411 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2013 | 2527 | 0.020 |
Why?
|
| Sexual Behavior | 1 | 2009 | 250 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2011 | 636 | 0.020 |
Why?
|
| Psychiatry | 1 | 2011 | 271 | 0.020 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2007 | 36 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2009 | 1134 | 0.020 |
Why?
|
| Professional Practice | 1 | 2007 | 43 | 0.020 |
Why?
|
| Lymphocytes | 2 | 2002 | 440 | 0.020 |
Why?
|
| Fatty Acids | 2 | 2002 | 370 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2010 | 1439 | 0.020 |
Why?
|
| Awareness | 1 | 2007 | 80 | 0.020 |
Why?
|
| Hematologic Tests | 1 | 2006 | 37 | 0.020 |
Why?
|
| Self Disclosure | 1 | 2006 | 26 | 0.020 |
Why?
|
| Quality Control | 1 | 2006 | 127 | 0.020 |
Why?
|
| Medical Audit | 1 | 2006 | 101 | 0.020 |
Why?
|
| Hypertension, Pulmonary | 1 | 2010 | 467 | 0.020 |
Why?
|
| Anemia | 1 | 2009 | 350 | 0.020 |
Why?
|
| Focus Groups | 1 | 2006 | 214 | 0.020 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2006 | 172 | 0.010 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2008 | 849 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 2006 | 319 | 0.010 |
Why?
|
| B7-2 Antigen | 1 | 2004 | 16 | 0.010 |
Why?
|
| Myeloblastin | 1 | 2004 | 19 | 0.010 |
Why?
|
| L-Selectin | 1 | 2004 | 22 | 0.010 |
Why?
|
| Professional Competence | 1 | 2005 | 99 | 0.010 |
Why?
|
| CD11b Antigen | 1 | 2004 | 40 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 2004 | 132 | 0.010 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2004 | 39 | 0.010 |
Why?
|
| Metabolic Syndrome | 1 | 2008 | 366 | 0.010 |
Why?
|
| alpha 1-Antitrypsin | 1 | 2004 | 85 | 0.010 |
Why?
|
| DNA, Ribosomal | 1 | 2003 | 56 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 2004 | 342 | 0.010 |
Why?
|
| Serine Endopeptidases | 1 | 2004 | 204 | 0.010 |
Why?
|
| Immunoglobulin Idiotypes | 1 | 2003 | 10 | 0.010 |
Why?
|
| Genes, Immunoglobulin | 1 | 2003 | 34 | 0.010 |
Why?
|
| Esterification | 1 | 2002 | 13 | 0.010 |
Why?
|
| Risk-Taking | 1 | 2003 | 105 | 0.010 |
Why?
|
| Asthma | 1 | 2010 | 811 | 0.010 |
Why?
|
| Income | 1 | 2003 | 141 | 0.010 |
Why?
|
| Demography | 1 | 2003 | 247 | 0.010 |
Why?
|
| Patient Selection | 1 | 2006 | 734 | 0.010 |
Why?
|
| Lipolysis | 1 | 2002 | 80 | 0.010 |
Why?
|
| Glycerol | 1 | 2002 | 99 | 0.010 |
Why?
|
| Insurance, Health | 1 | 2003 | 144 | 0.010 |
Why?
|
| Triglycerides | 1 | 2004 | 613 | 0.010 |
Why?
|
| Cholesterol | 1 | 2004 | 574 | 0.010 |
Why?
|
| Adipocytes | 1 | 2002 | 160 | 0.010 |
Why?
|
| Education, Medical | 1 | 2005 | 304 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 2002 | 465 | 0.010 |
Why?
|
| Organ Size | 1 | 2002 | 466 | 0.010 |
Why?
|
| Hepacivirus | 1 | 2003 | 273 | 0.010 |
Why?
|
| Seroepidemiologic Studies | 1 | 2001 | 145 | 0.010 |
Why?
|
| Fasting | 1 | 2002 | 310 | 0.010 |
Why?
|
| Hepatocytes | 1 | 2002 | 242 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2003 | 746 | 0.010 |
Why?
|
| Morbidity | 1 | 2001 | 255 | 0.010 |
Why?
|
| DNA | 1 | 2006 | 1675 | 0.010 |
Why?
|
| Hepatitis B | 1 | 2001 | 172 | 0.010 |
Why?
|
| Disease Management | 1 | 2003 | 560 | 0.010 |
Why?
|
| Lipid Metabolism | 1 | 2002 | 378 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2004 | 1153 | 0.010 |
Why?
|
| Adipose Tissue | 1 | 2002 | 499 | 0.010 |
Why?
|
| Mercaptoethanol | 1 | 1998 | 5 | 0.010 |
Why?
|
| Binding Sites, Antibody | 1 | 1998 | 100 | 0.010 |
Why?
|
| Phthiraptera | 1 | 1997 | 1 | 0.010 |
Why?
|
| Siphonaptera | 1 | 1997 | 7 | 0.010 |
Why?
|
| Immunity | 1 | 1998 | 188 | 0.010 |
Why?
|
| Molecular Epidemiology | 1 | 1997 | 162 | 0.010 |
Why?
|
| Research Design | 1 | 2001 | 754 | 0.010 |
Why?
|
| Energy Metabolism | 1 | 2002 | 809 | 0.010 |
Why?
|
| Jews | 1 | 1997 | 34 | 0.010 |
Why?
|
| Histocompatibility Testing | 1 | 1997 | 151 | 0.010 |
Why?
|
| Sulfur Dioxide | 1 | 1996 | 5 | 0.010 |
Why?
|
| Orthomyxoviridae | 1 | 1996 | 52 | 0.010 |
Why?
|
| Adenoviruses, Human | 1 | 1996 | 99 | 0.010 |
Why?
|
| Disease Reservoirs | 1 | 1995 | 37 | 0.010 |
Why?
|
| Cat-Scratch Disease | 1 | 1995 | 32 | 0.010 |
Why?
|
| Antigen-Antibody Complex | 1 | 1995 | 67 | 0.010 |
Why?
|
| Complement System Proteins | 1 | 1995 | 61 | 0.010 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 1996 | 151 | 0.010 |
Why?
|
| Bacteriological Techniques | 1 | 1995 | 87 | 0.010 |
Why?
|
| Temperature | 1 | 1996 | 330 | 0.010 |
Why?
|
| Immunization | 1 | 1996 | 315 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 1997 | 1124 | 0.010 |
Why?
|
| HLA Antigens | 1 | 1995 | 253 | 0.010 |
Why?
|
| Mutation | 1 | 2008 | 6289 | 0.010 |
Why?
|
| Liver | 1 | 2001 | 1867 | 0.010 |
Why?
|
| Glycoproteins | 1 | 1996 | 379 | 0.010 |
Why?
|
| Viral Proteins | 1 | 1995 | 360 | 0.010 |
Why?
|
| Pedigree | 1 | 1997 | 1694 | 0.010 |
Why?
|
| Drug Interactions | 1 | 1994 | 261 | 0.010 |
Why?
|
| RNA, Bacterial | 1 | 1992 | 55 | 0.010 |
Why?
|
| Reactive Oxygen Species | 1 | 1995 | 525 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2003 | 3843 | 0.010 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 1992 | 153 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 1995 | 501 | 0.010 |
Why?
|
| Brain | 1 | 2003 | 3217 | 0.010 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 1992 | 404 | 0.010 |
Why?
|
| Seizures | 1 | 1994 | 889 | 0.000 |
Why?
|
| Apoptosis | 1 | 1995 | 1931 | 0.000 |
Why?
|
| Base Sequence | 1 | 1992 | 3171 | 0.000 |
Why?
|
| Molecular Sequence Data | 1 | 1992 | 3970 | 0.000 |
Why?
|
| Phenotype | 1 | 1995 | 4532 | 0.000 |
Why?
|
| Child, Preschool | 1 | 1996 | 14776 | 0.000 |
Why?
|